Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.73 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | HDAC8 | Q9BY41 | 5/20 | 0.50 |
| ▸ | HDAC1 | Q13547 | 4/20 | 0.49 |
| ▸ | HDAC6 | Q9UBN7 | 4/20 | 0.49 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.45 |
| ▸ | CA2 | P00918 | 1/20 | 0.45 |
| ▸ | CA9 | Q16790 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | PYGL | P06737 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1459456 | 0.87 | ALDH1A1 (0.71) | ALDH1A1MEN1KMT2AHDAC8HDAC1 | |
| SCHEMBL10201340 | 0.85 | CA1 (0.57) | ALDH1A1MEN1KMT2AHDAC1HDAC6 | |
| SCHEMBL3791892 | 0.83 | ALDH1A1 (0.60) | ALDH1A1MEN1KMT2AEPHX1MAPT | |
| SCHEMBL27951759 | 0.81 | MAPT (0.71) | ALDH1A1MEN1KMT2AHDAC8HDAC1 | |
| SCHEMBL2388970 | 0.81 | EPHX1 (0.70) | ALDH1A1MEN1KMT2AEPHX1MAPT | |
| SCHEMBL10632586 | 0.80 | ALDH1A1 (0.61) | ALDH1A1MEN1KMT2AHDAC8HDAC1 | |
| SCHEMBL10632577 | 0.80 | ALDH1A1 (0.61) | ALDH1A1MEN1KMT2AHDAC8HDAC1 | |
| SCHEMBL13100053 | 0.79 | NPC1 (0.56) | ALDH1A1MEN1KMT2AHDAC8HDAC1 | |
| SCHEMBL21678186 | 0.79 | ALDH1A1 (0.60) | ALDH1A1MEN1KMT2AEPHX1MAPT | |
| SCHEMBL30508348 | 0.79 | NPC1 (0.56) | ALDH1A1MEN1KMT2AHDAC8HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10072000-B2 | Method of treating insomnia with halogenated pyrazolo[1,5-a]pyrimidines | FERRER INTERNACIONAL, S.A. (ES) | 2018-09-11 | — | — | US | disclosed |
| US-20160368912-A9 | HALOGENATED PYRAZOLO[1,5-A]PYRIMIDINES, PROCESSES, USES, COMPOSITIONS AND INTERMEDIATES | FERRER INTERNACTIONAL, S.A. (ES) | 2016-12-22 | — | — | US | disclosed |
| US-20130331401-A1 | Halogenated Pyrazolo[1,5-A]Pyrimidines, Processes, Uses, Compositions and Intermediates | FERRER INTERNACTIONAL, S.A. (ES) | 2013-12-12 | — | — | US | disclosed |
| US-20130331610-A1 | Halogenated Pyrazolo[1,5-A]Pyrimidines, Processes, Uses, Compositions and Intermediates | FERRER INTERNACIONAL, S.A. (ES) | 2013-12-12 | — | — | US | disclosed |
| US-8530482-B2 | Halogenated pyrazolo[1,5-A]pyrimidines, processes, uses, compositions and intermediates | FERRER INTERNACIONAL, S.A. (ES) | 2013-09-10 | — | — | US | disclosed |
| CN-101243089-B | Halopyrazolo [1,5-A ] pyrimidines, methods, uses as GABA-A receptor ligands, compositions and intermediate compounds | FERRER INT | 2011-07-06 | — | — | CN | disclosed |
| EP-1899343-B1 | HALOGENATED PYRAZOLO [1,5-A]PYRIMIDINES, PROCESSES, USES AS GABA-A RECEPTORS LIGAND, COMPOSITIONS AND INTERMEDIATES | FERRER INT (ES) | 2010-05-12 | — | — | EP | disclosed |
| US-20090111848-A1 | Halogenated Pyrazolo[1,5-A]Pyrimidines, Processes, Uses, Compositions and Intermediates | FERRER INTERNACIONAL, S.A. (ES) | 2009-04-30 | — | — | US | disclosed |
| CN-101243089-A | 3 Halopyrazolo 3 [ 3 1 3, 3 5 3- 3 A 3 ] 3 pyrimidines 3, 3 methods 3, 3 uses 3 as 3 GABA 3- 3 A 3 receptor 3 ligands 3, 3 compositions 3 and 3 intermediate 3 compounds 3 | FERRER INT (ES) | 2008-08-13 | — | — | CN | disclosed |
| EP-1899343-A1 | HALOGENATED PYRAZOLO [1,5-A]PYRIMIDINES, PROCESSES, USES AS GABA-A RECEPTORS LIGAND, COMPOSITIONS AND INTERMEDIATES | Ferrer Internacional, S.A. (ES) | 2008-03-19 | — | — | EP | disclosed |
| WO-2006136530-A1 | HALOGENATED PYRAZOLO [1,5-A]PYRIMIDINES, PROCESSES, USES AS GABA-A RECEPTORS LIGAND, COMPOSITIONS AND INTERMEDIATES | FERRER INTERNACIONAL, S.A. (ES) | 2006-12-28 | — | — | WO | disclosed |
| EP-1736475-A1 | Halogenated pyrazolo[1,5-a]pyrimidines, processes, uses, compositions and intermediates | FERRER INTERNACIONAL, S.A. (ES) | 2006-12-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130331401-A1 | Halogenated Pyrazolo[1,5-A]Pyrimidines, Processes, Uses, Compositions and Intermediates | GABRA5, GABRA1, RYR1 | ALDH1A1 684/4885MEN1 4216/4885KMT2A 843/4885 |
| US-10072000-B2 | Method of treating insomnia with halogenated pyrazolo[1,5-a]pyrimidines | GABRA5, GABRA1, GABBR1 | ALDH1A1 502/4885MEN1 4146/4885KMT2A 473/4885 |
| US-20130331610-A1 | Halogenated Pyrazolo[1,5-A]Pyrimidines, Processes, Uses, Compositions and Intermediates | GABRA5, GABRA1, RYR1 | ALDH1A1 684/4885MEN1 4216/4885KMT2A 843/4885 |
| US-20160368912-A9 | HALOGENATED PYRAZOLO[1,5-A]PYRIMIDINES, PROCESSES, USES, COMPOSITIONS AND INTERMEDIATES | GABRA5, GABRA1, RYR1 | ALDH1A1 684/4885MEN1 4216/4885KMT2A 843/4885 |
| US-20090111848-A1 | Halogenated Pyrazolo[1,5-A]Pyrimidines, Processes, Uses, Compositions and Intermediates | GABRA5, GABRA1, RYR1 | ALDH1A1 684/4885MEN1 4216/4885KMT2A 843/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.